BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee S, Cho YY, Cho EJ, Yu SJ, Lee JH, Yoon JH, Kim YJ. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. Int J Mol Med 2018;42:2551-9. [PMID: 30106087 DOI: 10.3892/ijmm.2018.3807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Zhang Y, Shi X, Li J, Wang L, Xie C, Wang Y. Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. Front Oncol 2022;12:836333. [DOI: 10.3389/fonc.2022.836333] [Reference Citation Analysis]
2 Ramírez-Flores PN, Barraza-Reyna PJ, Aguirre-Vázquez A, Camacho-Moll ME, Guerrero-Beltrán CE, Resendez-Pérez D, González-Villasana V, Garza-González JN, Silva-Ramírez B, Castorena-Torres F, Bermúdez de León M. Isotretinoin and Thalidomide Down-Regulate c-MYC Gene Expression and Modify Proteins Associated with Cancer in Hepatic Cells. Molecules 2021;26:5742. [PMID: 34641286 DOI: 10.3390/molecules26195742] [Reference Citation Analysis]
3 Lee J, Hong EM, Kim JH, Kim JH, Jung JH, Park SW, Koh DH, Jang HJ. Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition. Mol Biol Rep 2021;48:6231-40. [PMID: 34392440 DOI: 10.1007/s11033-021-06331-y] [Reference Citation Analysis]
4 Zhang H, Xu H, Zhang C, Tang Q, Bi F. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov 2021;7:207. [PMID: 34365464 DOI: 10.1038/s41420-021-00589-8] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
5 Huang TE, Deng YN, Hsu JL, Leu WJ, Marchesi E, Capobianco ML, Marchetti P, Navacchia ML, Guh JH, Perrone D, Hsu LC. Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells. Front Pharmacol 2020;11:599067. [PMID: 33343369 DOI: 10.3389/fphar.2020.599067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhao W, Bai B, Hong Z, Zhang X, Zhou B. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells. ACS Omega 2020;5:24838-47. [PMID: 33015502 DOI: 10.1021/acsomega.0c03527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]